Summaries of Symposia Conducted in Conjunction with the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists

[1]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[2]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[3]  E. Benjamin,et al.  Thyroid function and left ventricular structure and function in the Framingham Heart Study. , 2010, Thyroid : official journal of the American Thyroid Association.

[4]  M. Vanderpump,et al.  The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. , 2010, The Journal of clinical endocrinology and metabolism.

[5]  C. Rosebraugh,et al.  Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. , 2010, The New England journal of medicine.

[6]  W. Schaffner,et al.  Acute selenium toxicity associated with a dietary supplement. , 2010, Archives of internal medicine.

[7]  H. Rodbard,et al.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  Jiang He,et al.  Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes , 2009, Annals of Internal Medicine.

[9]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[10]  Samy Suissa,et al.  Renal and retinal effects of enalapril and losartan in type 1 diabetes. , 2009, The New England journal of medicine.

[11]  R. Berria,et al.  Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.

[12]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[13]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[14]  E. Vittinghoff,et al.  Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. , 2008, Journal of the American College of Cardiology.

[15]  R. DeFronzo,et al.  Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study , 2008, Current medical research and opinion.

[16]  Curt D. Furberg,et al.  Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.

[17]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[18]  L. Palinkas,et al.  Psychoneuroendocrine effects of combined thyroxine and triiodothyronine versus tyrosine during prolonged Antarctic residence , 2007, International journal of circumpolar health.

[19]  I. Klein,et al.  Thyroid disease and the heart. , 2007, Circulation.

[20]  J. Papadakis,et al.  Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. , 2007, Thyroid : official journal of the American Thyroid Association.

[21]  B. Brenner,et al.  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. , 2007, Journal of the American Society of Nephrology : JASN.

[22]  D. Dazzi,et al.  The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. , 2007, The Journal of clinical endocrinology and metabolism.

[23]  Jay S. Skyler,et al.  Is There a Place for Insulin Pump Therapy in Your Practice , 2007 .

[24]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[25]  M. Schenker,et al.  Essentials of Medical Geology: Impacts of the Natural Environment on Public Health , 2005, Science.

[26]  I. Bucci,et al.  Zinc sulfate supplementation improves thyroid function in hypozincemic down children , 1999, Biological Trace Element Research.

[27]  A. Ljubić,et al.  [Use of continuous subcutaneous insulin infusion by a portable insulin pump during pregnancy in women with type 1 diabetes mellitus]. , 2006, Vojnosanitetski pregled.

[28]  E. Vittinghoff,et al.  Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. , 2006, The American journal of medicine.

[29]  M. Taskinen,et al.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes , 2006, Diabetologia.

[30]  S. M. Storms,et al.  In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. , 2006, Diabetes technology & therapeutics.

[31]  J. Pickup,et al.  Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability , 2006, Diabetes/metabolism research and reviews.

[32]  W. Insull.  Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review , 2006, Southern medical journal.

[33]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[34]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[35]  E. Lewis,et al.  Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. , 2005, Journal of the American Society of Nephrology : JASN.

[36]  I. Harman-boehm,et al.  Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[37]  Ray Burke,et al.  A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. , 2005, Diabetes care.

[38]  R. Becker,et al.  A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  G. Leoncini,et al.  Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.

[40]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[41]  D. Tsikas,et al.  Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. , 2005, Journal of the American Society of Nephrology : JASN.

[42]  I. Hirsch,et al.  Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.

[43]  Salim Yusuf,et al.  Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. , 2005, American heart journal.

[44]  R. Trevisan,et al.  Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study. , 2004, Diabetes, nutrition & metabolism.

[45]  Kyuzi Kamoi,et al.  A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. , 2004, Diabetes research and clinical practice.

[46]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[47]  A. Collins,et al.  Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.

[48]  M. Burge,et al.  Effects of kelp supplementation on thyroid function in euthyroid subjects. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[49]  D. Bruttomesso,et al.  Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy , 2003, Acta Diabetologica.

[50]  S. Mudaliar,et al.  Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. , 2003, Diabetes care.

[51]  C. Homko,et al.  Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. , 2003, Diabetes care.

[52]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[53]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[54]  Gernot Brunner,et al.  A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. , 2002, Diabetes care.

[55]  Johannes W. Dietrich,et al.  Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. , 2002, The Journal of clinical endocrinology and metabolism.

[56]  P. Raskin,et al.  Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. , 2002, Diabetes care.

[57]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[58]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[59]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[60]  A. Gotto,et al.  Pleiotropic effects of statins: do they matter? , 2001, Current opinion in lipidology.

[61]  Jerome D. Cohen.  ABCs of secondary prevention of CHD: easier said than done , 2001, The Lancet.

[62]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[63]  P. Kaufmann,et al.  Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[64]  S. Gabbe,et al.  Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. , 2000, American journal of obstetrics and gynecology.

[65]  P. Libby.  Changing concepts of atherogenesis , 2000, Journal of internal medicine.

[66]  G. Canaris,et al.  The Colorado thyroid disease prevalence study. , 2000, Archives of internal medicine.

[67]  A. Hofman,et al.  Subclinical Hypothyroidism Is an Independent Risk Factor for Atherosclerosis and Myocardial Infarction in Elderly Women: The Rotterdam Study , 2000, Annals of Internal Medicine.

[68]  Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[69]  C. White.  Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. , 1998, The American journal of medicine.

[70]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[71]  D. Levy,et al.  Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. , 1997, Circulation.

[72]  S. Grundy,et al.  Management of Dyslipidemia in NIDDM , 1990, Diabetes Care.